Boehringer Ingelheim acquires Pharmaxis' phase 1a drug
Boehringer Ingelheim and Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences.
Bronchitol Paediatric Cystic Fibrosis Clinical Trial Reports Positive Results
Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to announce positive results of its recently completed Phase II trial of Bronchitol® (mannitol) in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients, regardless of concomitant dornase alfa use.
Pharmaxis in the news
Bennelong Innovation Forum
Pharmaxis CEO Gary Phillips was a key speaker at the inaugural Bennelong Innovation Forum attended by the Minister for Health, Sussan Ley, at Macquarie University on 9 December.
Pharmaxis CEO Gary Phillips speaks to The Australian about policy to support the commercialisation of biomedical research.